Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.4509 -0.0339 (-6.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 829,874
Open 0.4900
Bid (Size) 0.4700 (2)
Ask (Size) 0.4800 (8)
Prev. Close 0.4848
Today's Range 0.4421 - 0.5089
52wk Range 0.2911 - 3.757
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
Where Sangamo Therapeutics Stands With Analysts
Via Benzinga

Performance

YTD
-85.64%
-85.64%
1 Month
+2.11%
+2.11%
3 Month
-53.23%
-53.23%
6 Month
-64.21%
-64.21%
1 Year
-87.26%
-87.26%

More News

Read More
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
Via Benzinga
Analyst Ratings for Sangamo Therapeutics
Via Benzinga
A Preview Of Sangamo Therapeutics's Earnings
Via Benzinga
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
From Sangamo Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 1, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.